National Health Surveillance Agency (Anvisa) approved the molecule sotorasibe, developed to attack the lung cancer not small cells. The drug is specifically aimed at those who have a mutation in the gene K-RAS G12C . “K-RAS was discovered 40 years ago and, so far, there was no therapy against it. And about 13% of lung cancer cases are linked to a mutation particularly in the K-RAS G12C ”, observes oncologist Alejandro Arancibia, medical director of Amgen Brasil. It may seem very specific, but lung cancer is so common that a small percentage of people with each genetic type already represent a robust group.  To give you an idea, the country had about 30 thousand new cases and 29 thousand deaths from the disease in 2020, according to the most recent data released by. National Cancer Institute (Inca). [abril-whatsapp] [/ abril-whatsapp] The function of the sotorasibe molecule is. increase patient survival. It will be useful to whom has already undergone some other therapy and progress has been made. “The basic treatment of any malignant tumor may involve surgery, chemotherapy and immunotherapy. After these procedures, this molecule comes to increase the individual’s survival as a less invasive solution ”, summarizes the oncologist. The medicine is taken. orally. Remembering that, until then, there was no reinforcement like this to fight this type of cancer. Then the patient ended up going through new cycles of chemotherapy, for example.  Source: Innovative medicine against lung cancer is approved by Anvisa – Mágica Mistura 車